Most care management programs track appointment adherence as a single number: the no-show rate. It shows up in operational dashboards, gets reported in quarterly reviews, and generates the occasional directive to "improve patient follow-up." What it rarely does is tell a care team which patients are actually in trouble — and why.
No-show rate is a lagging indicator. By the time a patient has accumulated enough missed appointments to register as a problem in a retrospective report, the clinical window for low-cost intervention has often passed. The metrics that actually matter for chronic disease management are the ones that capture the sequence of missed touchpoints — and that requires looking at appointment adherence in combination with pharmacy adherence, diagnostic completion, and communication responsiveness.
Why No-Show Rate Alone Misleads
A patient who no-shows once in twelve months is clinically very different from a patient who no-shows once in six weeks. A patient who misses a routine diabetic foot exam is different from a patient who misses a titration visit for their lisinopril after a recent blood pressure spike. These distinctions disappear when everything collapses into a single no-show percentage.
The other problem with no-show rate as a primary metric is that it doesn't account for rescheduling behavior. In practice, there's a meaningful clinical difference between a patient who cancels and rebooks and a patient who simply doesn't come. The first is an adherence friction issue; the second is often a disengagement signal. Many EHR systems don't distinguish these cleanly in their scheduling modules, so the downstream care management reports treat them the same.
The Sequence Signal: What Actually Predicts Deterioration
When we look at chronic patients who experienced a preventable readmission or an acute exacerbation that required urgent care, the precursor pattern almost always involves a sequence of disengagement signals, not a single missed appointment. Typically, the sequence looks like this:
- Pharmacy refill gap: the patient misses a refill on a maintenance medication by 7 to 14 days.
- Appointment no-show without rescheduling within 72 hours.
- No response to outreach (SMS reminder, portal message) within 48 hours of the no-show.
- Second missed refill or laboratory draw (HbA1c, BMP, INR depending on condition).
By the time step 4 occurs, the patient has been in a care gap for three to six weeks. Most care management systems surface this patient at step 4 — or sometimes not until the ADT event from an ED visit fires. The question worth asking is: what would a care coordinator have needed to see at step 1 to intervene before the sequence compounded?
HEDIS Measures and Their Limitations
HEDIS measures like Comprehensive Diabetes Care (CDC), Controlling High Blood Pressure (CBP), and Medication Management for People with Asthma (MMA) are the standard quality benchmarks for chronic disease management under Medicare Advantage and commercial VBC contracts. They provide a consistent framework for measurement and reporting, and health plans use them to assess ACO and MSSP performance.
The limitation is that HEDIS measures are annual. They measure whether a specific action was completed within a 12-month measurement period — not whether the patient is engaged right now. A COPD patient who completed their spirometry in February but has since missed three albuterol refills and two follow-up visits will look fine on a year-to-date HEDIS report in April. The measure doesn't capture the deterioration that's likely underway in real time.
This isn't a criticism of HEDIS — the annual measurement framework is appropriate for its purpose. It's a recognition that HEDIS compliance and current clinical risk are not the same thing, and care management workflows that are primarily organized around HEDIS gap closure often miss the patient who is actively disengaging between measurement windows.
Medication Possession Ratio: A Better Signal, Still Imperfect
Medication possession ratio (MPR) and proportion of days covered (PDC) are pharmacy-based adherence metrics that give a more continuous picture than appointment records alone. An MPR below 0.80 on a maintenance medication like metformin, atorvastatin, or an ACE inhibitor is a clinically meaningful signal — and it's available from PBM claims data on a rolling basis, not just annually.
PDC is generally preferred over MPR for chronic disease adherence because it caps at 1.0 and handles early refills more cleanly. For MSSP and many commercial ACO contracts, PDC on specific drug classes is a quality measure that directly affects shared savings calculations. When a patient's PDC for antihypertensives drops below 0.80 in the middle of a performance period, that's not just a clinical concern — it's a quality metric that will affect the organization's year-end reconciliation.
The practical challenge with MPR and PDC is data latency. PBM claims typically lag by 7 to 14 days, and some health systems don't have integrated pharmacy data feeds at all. When a patient misses a refill today, that signal may not appear in any care management system until two weeks later — and even then, only if someone is explicitly running that query.
The Metric That Most Programs Don't Track: Communication Responsiveness
One of the most predictive signals for impending disengagement isn't in the clinical record at all — it's in how patients respond to outreach. A patient who consistently answers reminder calls, responds to SMS confirmations, and opens portal messages is behaviorally different from one who doesn't. When a previously responsive patient stops acknowledging outreach, that behavioral shift often precedes a clinical care gap by one to three weeks.
Most care management platforms don't operationalize this signal. Outreach attempts are logged, but the response pattern over time — whether it's trending toward non-response — isn't scored or surfaced. The coordinator who makes the call knows that the patient "used to always answer," but that institutional memory doesn't automatically translate into a prioritized worklist item.
This is one of the areas where the design of Patientrig's alert logic focuses: the change in responsiveness pattern as an independent signal, layered on top of pharmacy and appointment data. A patient who has been reliably engaging and suddenly goes quiet warrants earlier intervention than the chronically non-responsive patient who requires more intensive outreach strategies.
What a Composite Adherence Score Looks Like in Practice
The most useful framing for care teams isn't any single metric — it's a composite view that combines appointment adherence (with rescheduling behavior), PDC on primary maintenance medications, lab/diagnostic completion against care plan expectations, and recent communication responsiveness. Weighted differently depending on the clinical condition:
- For a CHF patient: medication adherence to ACE inhibitors/ARBs and loop diuretics carries more weight than appointment timing, because a missed furosemide dose will cause fluid retention before a missed clinic visit causes a detectable change.
- For a Type 2 diabetic patient: HbA1c recency and metformin PDC are primary; appointment adherence matters but the glycemic deterioration from medication lapses often outpaces the appointment-based warning signal.
- For a hypertensive patient on a BP monitoring protocol: the absence of blood pressure readings (whether from home monitoring or in-office visits) is itself the signal, independent of whether an appointment was technically kept.
We're not saying that no-show rate is worthless — it's a reasonable operational efficiency metric and it matters for scheduling management. What we are saying is that no-show rate as a proxy for patient health trajectory is a category error. The patients who are quietly deteriorating between visits are often perfectly good at keeping the appointments that remain scheduled. Their deterioration is happening in the gaps, and the gaps show up in pharmacy data and lab completion before they show up in the scheduling system.
Making This Actionable for Care Teams
The practical takeaway for care coordinators and VBC operations leaders is this: if your care gap reports are organized primarily around scheduled appointment adherence, you are likely seeing a subset of your actual at-risk population — and the subset you're missing is often the one that generates your most expensive utilization events.
Re-orienting care gap identification around a composite signal — pharmacy PDC, diagnostic completion, and outreach responsiveness alongside appointment data — requires either a well-integrated population health tool or, at minimum, a care coordinator workflow that pulls pharmacy and lab feeds alongside scheduling data before morning huddle. The former is more scalable; the latter is what most programs are actually running today, and there's real clinical value in getting it right even within that constraint.
The metric that will matter most in your VBC contract review is the one your program didn't track until after the readmission happened. The goal is to close that gap — not by adding more metrics, but by choosing the ones that tell you something about what's happening now, not what happened last quarter.
